Literature DB >> 8720608

Lack of relationship between muscle sympathetic nerve activity and skeletal muscle vasodilation in response to insulin infusion.

M Spraul1, E Ravussin, A D Baron.   

Abstract

Increases in plasma insulin concentration result in vasodilation in skeletal muscle but also in an increase in muscle sympathetic nerve activity (MSNA) which is thought to cause vasoconstriction. The increase in MSNA could therefore be a response to vasodilation (baroreflex), or MSNA could cause vasodilation via putative sympathetic vasodilatory fibres. To examine the relationship between vasodilation, MSNA and insulin action we studied nine non-diabetic Pima Indian men (age 29 +/- 7 years, weight 91 +/- 19 kg, 29 +/- 6% body fat, mean +/- SD) during sequential euglycaemic clamps at low and high insulin doses (80 and 600 mU.m-2.min-1). Leg blood flow was measured by thermodilution, leg glucose uptake by the balance technique, arterial pressure by invasive monitoring and MSNA by microneurography of the peroneal nerve. Whole body glucose uptake (M) ranged from 6.7 to 48.3 during low dose and from 9.4 to 67.7 mumol kg fat free mass-1.min-1 during high dose insulin infusion. At both insulin doses, incremental leg blood flow correlated with M (r = 0.63 and 0.71, respectively). No correlation was found between incremental MSNA and leg blood flow, M or leg glucose uptake. Blood pressure was unchanged throughout the study. MSNA increased after 15-40 min of insulin infusion in all the subjects, whereas leg blood flow started to increase only after 45 min in the most insulin sensitive but not in the most insulin resistant subjects. Thus, insulin stimulates MSNA more rapidly than vasodilation. In conclusion, insulin-mediated MSNA: 1) is neither a response to nor a cause of the vasodilation observed in insulin sensitive men, 2) has no net pressor effect even in the most insulin resistant men in whom insulin-mediated vasodilation was impaired. We conclude that the effect of insulin to stimulate MSNA is dissociated from its acute haemodynamic action.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8720608     DOI: 10.1007/BF00400418

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  23 in total

1.  Sympathetic response to oral carbohydrate administration. Evidence from microelectrode nerve recordings.

Authors:  C Berne; J Fagius; F Niklasson
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

2.  Comparison of dye-dilution and plethysmographic blood flow measurements: an evaluation of the influence of invasive techniques on blood flow and on arterial and femoral venous substrate variables in man.

Authors:  L Jorfeldt; H Rutberg
Journal:  Clin Sci (Lond)       Date:  1990-07       Impact factor: 6.124

3.  Kinetics of in vivo muscle insulin-mediated glucose uptake in human obesity.

Authors:  M Laakso; S V Edelman; J M Olefsky; G Brechtel; P Wallace; A D Baron
Journal:  Diabetes       Date:  1990-08       Impact factor: 9.461

Review 4.  Why is insulin not a risk factor for coronary heart disease?

Authors:  R J Jarrett
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

5.  Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man.

Authors:  J W Rowe; J B Young; K L Minaker; A L Stevens; J Pallotta; L Landsberg
Journal:  Diabetes       Date:  1981-03       Impact factor: 9.461

6.  Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans.

Authors:  A D Baron; G Brechtel; P Wallace; S V Edelman
Journal:  Am J Physiol       Date:  1988-12

7.  Muscle sympathetic nerve activity in response to glucose ingestion. Impact of plasma insulin and body fat.

Authors:  M Spraul; E A Anderson; C Bogardus; E Ravussin
Journal:  Diabetes       Date:  1994-02       Impact factor: 9.461

8.  Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake.

Authors:  A D Baron; H Steinberg; G Brechtel; A Johnson
Journal:  Am J Physiol       Date:  1994-02

9.  Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians.

Authors:  S Lillioja; D M Mott; M Spraul; R Ferraro; J E Foley; E Ravussin; W C Knowler; P H Bennett; C Bogardus
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

10.  Insulin deficiency rather than hyperinsulinaemia in newly diagnosed type 2 diabetes mellitus.

Authors:  M J Davies; J Metcalfe; I P Gray; J L Day; C N Hales
Journal:  Diabet Med       Date:  1993-05       Impact factor: 4.359

View more
  5 in total

1.  Out-of-Clinic Sympathetic Activity Is Increased in Patients With Masked Uncontrolled Hypertension.

Authors:  Mohammed Siddiqui; Eric K Judd; Byron C Jaeger; Hemal Bhatt; Tanja Dudenbostel; Bin Zhang; Lloyd J Edwards; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2019-01       Impact factor: 10.190

2.  Role of the arterial baroreflex in the sympathetic response to hyperinsulinemia in adult humans.

Authors:  Neil J McMillan; Rogerio N Soares; Jennifer L Harper; Brian Shariffi; Alfonso Moreno-Cabañas; Timothy B Curry; Camila Manrique-Acevedo; Jaume Padilla; Jacqueline K Limberg
Journal:  Am J Physiol Endocrinol Metab       Date:  2022-02-21       Impact factor: 4.310

Review 3.  Role of the Autonomic Nervous System in the Hemodynamic Response to Hyperinsulinemia-Implications for Obesity and Insulin Resistance.

Authors:  Jacqueline K Limberg; Rogerio N Soares; Jaume Padilla
Journal:  Curr Diab Rep       Date:  2022-03-05       Impact factor: 4.810

4.  Is insulin the new intermittent hypoxia?

Authors:  Jacqueline K Limberg; Timothy B Curry; Nanduri R Prabhakar; Michael J Joyner
Journal:  Med Hypotheses       Date:  2014-03-18       Impact factor: 1.538

Review 5.  Gene and environmental interactions according to the components of lifestyle modifications in hypertension guidelines.

Authors:  Yoshihiro Kokubo; Sandosh Padmanabhan; Yoshio Iwashima; Kazumasa Yamagishi; Atsushi Goto
Journal:  Environ Health Prev Med       Date:  2019-03-11       Impact factor: 3.674

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.